ACHCAcadia Healthcare Company, Inc.
Is the price fair?
In its normal P/E range. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
In its normal range: P/E 21.0 vs a 21.6 median over 22 quarters (−3% vs median).
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What ACHC's price assumes
Acadia Healthcare Company, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 0.72× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 1.23
Price / book · today's price, trailing year to Mar 31, 2026
- EV / sales
- 1.42
EV / sales
Details›
- Price / booktoday's price, trailing year to Mar 31, 2026
- 1.23
- EV / EBIToperating margin −32%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Mar 31, 2026
- 1.42
- Market capitalisation
- $2.41B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.